CD4 and neoplasm: One of these agents, bortezomib, inhibits the numbers and functions of activated normal naïve B, memory B, plasma cells, and CD4 T cells, whereas it increases regulatory T cell numbers and enhances NK cell-mediated anti-tumor responses (63).